Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Adu, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adu, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1536-1538
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

The evidence base for the treatment of lupus nephritis in the new millennium

Dwomoa Adu

Department of Nephrology, Queen Elizabeth Hospital, Birmingham, UK

Keywords: lupus nephritis

Introduction

At the start of the new millennium, it is important to reassess progress in the treatment of lupus nephritis. The aims of treating lupus nephritis are to induce and maintain remission thereby reducing the risks of progression to renal failure and of dying. At the same time, patients with lupus nephritis may have extra-renal disease, the most severe of which is central nervous system disease and this requires treatment. A further and important aim is to minimize treatment-related toxicity. Prednisolone and cyclophosphamide are accepted as the optimal treatment for proliferative lupus nephritis [1] but have substantial toxicities. What then is the evidence base for the treatment of lupus nephritis and why does the treatment of lupus nephritis still generate such strong differences of opinion?

Steroids plus alkylating agents or azathioprine

Patients with mesangial proliferation . . . [Full Text of this Article]

Plasma exchange

New treatment

MMF and lupus nephritis
Randomized controlled trials of MMF
Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
M J Lewis and D D'Cruz
Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus
Lupus, March 1, 2005; 14(3_suppl): s17 - s26.
[Abstract] [PDF]

Home page
 LupusHome page
M. Lewis and D. D'Cruz
Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus
Lupus, January 1, 2005; 14(1_suppl): s17 - s26.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. N. Wardle and D. Adu
Lupus nephritis in the new millennium
Nephrol. Dial. Transplant., March 1, 2002; 17(3): 519 - 519.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. K. Ghosh
Lupus nephritis: physicians' preparedness for communication of evidence-based therapy
Nephrol. Dial. Transplant., March 1, 2002; 17(3): 525 - 526.
[Full Text] [PDF]